PC-021 · antimicrobial · ll-37
LL-37
Cathelicidin
Also: CAP-18 · hCAP-18
§ Overview
The only human cathelicidin antimicrobial peptide. LL-37 is part of the innate immune system, produced by immune cells, epithelial cells, and keratinocytes. It has broad-spectrum antimicrobial activity against bacteria, viruses, and fungi, plus immunomodulatory and wound healing properties.
§ Mechanism
Disrupts microbial cell membranes through electrostatic interaction with negatively charged lipids. Also modulates immune response by chemotacting immune cells, neutralizing endotoxins (LPS), promoting angiogenesis, and influencing adaptive immunity through dendritic cell activation.
§ Common Uses
- → Infection resistance
- → Biofilm disruption
- → Immune support
- → Wound healing
- → Lyme disease support
§ Reported Side Effects
- · Injection site irritation
- · Mild inflammation at injection site
§ Research, Experiences & Trends
Mechanism of Action
Disrupts microbial cell membranes through electrostatic interaction with negatively charged lipids. Also modulates immune response by chemotacting immune cells, neutralizing endotoxins (LPS), promoting angiogenesis, and influencing adaptive immunity through dendritic cell activation.
Common Uses
Dosage & Pharmacology
Known Side Effects
- • Injection site irritation
- • Mild inflammation at injection site